Suspected Adverse Drug Reactions Associated with Leukotriene Receptor Antagonists Versus First Line Asthma Medications: A National Registry-Pharmacology Approach

Method databases

The Electronic Medicines Compendium (EMC), and the Chemical Database of bioactive molecules with drug-like properties European molecular Biology laboratory (ChEMBL) databases were used to identify the physiochemical properties, pharmacokinetics, and pharmacology data of montelukast, zafirlukast, beclomethasone, salbutamol. [15-18]

Physiochemical properties

The physicochemical properties included molecular weight, pK_a, ^tPSA, hydrogen bond donors and acceptors, clogD_7.4, whether it is a P-glycoprotein substrate and the clog₁₀P. The pIC₅₀ was calculated using the median IC₅₀ of the target homo sapien protein for each respective drug. The lipophilic ligand efficacy (LLE) was calculated as follows: LLE = pIC₅₀ - clog₁₀P (Table 1). [18]

Blood-Brain Barrier (BBB) penetration

The prediction of BBB penetration was by determined by whether the physiochemical properties of the drugs meet requirements and thresholds to allow for penetration. Specifically, molecular weight < 450 Da, ^tPSA <90 Å, neutral or basic characteristics based on pKa, < 6 hydrogen bond donors and < 2 hydrogen bond acceptors, a clogD_7.4 between 1-3, and ability to be a P-glycoprotein substrate. The more requirements met, the higher predicted BBB penetration. [19]

Pharmacokinetic properties

The pharmacokinetic properties included bioavailability (%F), half-life (t_1/2), T_max (time to reach the max concentration), C_max (peak plasma concentration), whether it was metabolised by a CYP P₄₅₀ enzyme isoform, renal clearance (Cl), volume of distribution (V_d), total clearance (L/h), and plasma protein binding (PPB). C_max was converted from ng/mL to nM. EMC, DrugBank, PubChem, ChEMBL and wider literature were used to find pharmacokinetic data, by searching for “drug name” and “parameter required” (Table 2). [15-18, 20-25]

Pharmacological properties

The ChEMBL database was used to collect the human single protein target bioactivity data for montelukast, zafirlukast, beclomethasone and salbutamol. [18] The median IC₅₀ values were used to determine a dependable pIC₅₀ value (Table 3).

Prescribing data

Prescription data in primary care across England was curated from OpenPrescribing (August 2018 and September 2023). [26] Prescription items (R_x) were collated to standardise the suspected adverse drug reactions (ADRs) per 100,000 R_x to factor in variations in prescription rates amongst the medications. A minimum of 100,000 R_x between 2018-2023 was an additional inclusion criterion.

Adverse drug reactions

Suspected ADR data was datamined from the Medicines and Healthcare products Regulatory Authority (MHRA) Yellow Card interactive Drug Analysis Profile (iDAP). Dates selected were January 2018 to November 2023 for single active constituents only. [27] System organ classes (SOC) with significant ADR rates across the medications and fatalities were selected. The ADR data required standardisation to allow for comparisons between the different drugs. ADRs per 100,000 R_x is a standard approach in signal hypothesis generation [18, 28-33] Drugs were compared to each other in terms of ADR SOCs (Table S2 and Table 4) to determine statistically significant signals and where P < .001, high level group terms (HLGT) were additionally explored (Table S3 and Table 5).

Molecular properties

The structures of the medications studied are shown in Figure 1.

• Download figure
• Open in new tab

Figure 1.

Structures of asthma medications studied (LRTAs: montelukast and zafirlukast, controls ICS: beclomethasone and SABA: salbutamol).

The physiochemical properties of montelukast, zafirlukast and the controls beclomethasone and salbutamol are displayed in Table 1.

Montelukast was the most lipophilic drug (clog₁₀P = 8.49) and zafirlukast is the most potent (pIC₅₀ = 8.74). Montelukast and zafirlukast both had an LLE significantly below 5 (0.15 and 2.34 respectively). The properties which met the requirements for BBB penetration are highlighted in green (Table 1). Salbutamol and beclomethasone met both the molecular weight requirement (<450 Da) and are either neutral or basic. Montelukast and salbutamol had a ^tPSA < 90 Å (70.42 Å and 72.72 Å respectively). No drugs had less than 2 hydrogen bond acceptors, however, all drugs had less than 6 hydrogen bond donors. Only beclomethasone had a clogD_7.4 between 1 and 3 (2.15). All drugs are P-glycoprotein substrates, but this mechanism declines with age.

Pharmacokinetic properties

The pharmacokinetic properties of the LTRAs and the controls are shown Table 2. Zafirlukast had the highest bioavailability of F = 100% (oral), while the lowest was salbutamol at 24.8%. The T_max was the same for montelukast and zafirlukast (3 h) but lower for beclomethasone and salbutamol (0.7 h and 0.17 h, respectively). All drugs were metabolised by cytochrome P₄₅₀ (CYP) familial isoforms. The V_d of salbutamol was highest (143.2 L) and the lowest was montelukast (8-11 L). Montelukast and zafirlukast had high plasma protein binding (PPB) of 99% compared to that of salbutamol at 10%.

Pharmacology properties

The pharmacology results show the clinically significant values in green with an inhibitory value below the C_max threshold (Table 3). A threshold was created (x1.5) to include off-target pharmacological activities that may fall outside the C_max due to differential dosing regimens. Montelukast was the most potent towards its target receptor, cysteinyl leukotriene receptor 1 (2.3 nM), then zafirlukast (8.7 nM). Montelukast showed potent interaction with off-target, adenosine A3 receptor (43 nM). Both montelukast and zafirlukast were potent towards off-target, MAP kinase p38 alpha (856 nM and 6.5 nM, respectively). Zafirlukast interacted with off-target, MAP kinase ERK2 (538 nM). Salbutamol was potent towards its on-target protein beta-2 adrenergic receptor (980 nM). Beclomethasone was potent towards its on-target receptor, glucocorticoid receptor (8.2 nM). Montelukast and zafirlukast were found to have potent interactions with additional off-target proteins (Table 3).

ADRs

Total ADRs and psychiatric ADRs were found to be statistically significant at SOC level (Table 4). Further exploration of psychiatric ADRs at HLGT level are shown in Table 5. Montelukast provided a much higher ADR rate per 100,000 R_x in multiple organ class categories including cardiac disorder 0.13 (compared to 0.1 and 0.06 beclomethasone and salbutamol respectively), gastrointestinal disorder (1.08), nervous system disorders (1.71) and psychiatric disorders (8.22) per 100,000 R_x. Montelukast was the only drug with a completed suicide ADR rate at 0.01 per 100,000 Rx, whereas the others were zero. Table 4 also shows that montelukast had a higher respiratory, thoracic, and mediastinal disorder than both beclomethasone and salbutamol but did not reach significance.

Total ADRs and fatalities

Zafirlukast was discontinued in 2018 due to commercial reasons. [34] This led to the drug not meeting the requirements for the inclusion criteria for the ADR/prescribing data collection as it had less than 100,000 Rx and therefore excluded from the discussion of addressing ADRs and fatalities.

Amongst all the drugs, montelukast had the highest ADR rate at 15.64 per 100,000 R_x, followed by beclomethasone at 3.37 and salbutamol at 1.2. Montelukast had significantly lower LLE compared to both beclomethasone and salbutamol (0.15 compared to 5.93 and 5.67) (Table 1). This implies greater promiscuity, and the data corroborates this, as montelukast potently inhibits two off-target proteins (Table 3). The highest rate for fatalities across the drugs was shared by both montelukast and salbutamol (0.01 per 100,000 R_x).

Psychiatric ADRs

All SOC ADRs analysed were found to not reach statistically significant except for psychiatric ADRs (Table 4). Montelukast (P < .001 provided the highest ADR rate at 8.22 per 100,000 R_x, which is logarithmically higher than the controls, beclomethasone, and salbutamol (0.24 and 0.06 per 100,000 R_x, respectively).

Further data-mining beyond SOCs to HLGTs (Table 5) revealed emerging trends between montelukast and the controls but in all cases did not reach statistical significance (P > .001). Anxiety disorders and symptoms (275 vs 70 reports for montelukast vs controls respectively), depressed mood disorders (162 vs 25 reports for montelukast vs controls respectively), disturbances in thinking and perception (76 vs 11 reports for montelukast vs controls respectively), mood disorders (182 vs 30 reports for montelukast vs controls respectively),, sleep disorders (411 vs 45 reports for montelukast vs controls respectively), and suicidal and self-injurious behaviours (96 vs 5 reports for montelukast vs controls respectively), showed clear trends with higher reports for montelukast for both directly suspected ADRs and when standardised to prescribing levels compared to the controls. Furthermore, two fatalities within the suicidal and self-injurious category emerged for montelukast compared to the controls (0 for both salbutamol and beclomethasone).

A previous study compared the side effects of antidepressants and immune modulators including montelukast, in human cell lines. Montelukast had a similar side effect profile to the atypical antidepressant, bupropion, which is a dopamine and norepinephrine reuptake inhibitor. [35] Montelukast impacts dopamine levels at a cellular level, despite not being pharmacologically relevant at the protein level based on a single dose C_max (Table 3). However, physiochemical data can only predict to a certain extent. Another study found that montelukast (at the recommended dose of 10 mg) was discovered in the cerebrospinal fluid (CSF) at a therapeutic dose. The central nervous system (CNS) was then evaluated afterwards to show that montelukast had penetrated the BBB significantly which differs from the predicted BBB in Table 1. [36] Furthermore a study of neuropsychiatric events in children, adolescents, and young adults taking montelukast found that montelukast accumulates in the CSF. [37]. This accumulation at levels sufficient to impact the dopamine receptor (7.7 µM, Table 3) may potentially explain some of the psychiatric side effects.

Cardiac ADRs and fatalities

Montelukast had a higher cardiac ADR rate at 0.13 per 100,000 R_X compared to both beclomethasone and salbutamol (Table 4). Suspected montelukast induced heart palpitations, were significantly higher (0.12) in comparison with beclomethasone and salbutamol (0.08 and 0.02 per 100,000 R_x).

Montelukast is only usually added to asthma treatment if a patient has not responded to first line treatment with salbutamol with regular low dose inhaled corticosteroid (beclomethasone) has not been successful as an alternative to an increased dose of inhaled corticosteroid, allowing management of symptoms via an alternative pharmacological pathway. [38-39]

Montelukast has off target interactions with Adenosine A3 receptor and MAP kinase p38 alpha. The interaction with MAP kinase p38 alpha may be a cause of the cardiac effects. The p38 MAPK pathway plays an integral role in cardiac contractility and cardiac remodelling, and thus inhibiting this protein may be a potential cause for the cardiac ADRs resulting with montelukast. [40] Cessation of montelukast was considered a possible trigger in a 53-year-old male endurance athlete who presented with a two-week history of symptomatic ventricular ectopics, confirmed by ECG and 24-hour tape. Other investigations were considered normal with no alternative identifiable causes for the arrhythmias which resolved 24 hours after re-starting the montelukast. [41]

Montelukast also inhibits adenosine A3 receptor this has a significant role in myocardial infarction and atherosclerosis. Adenosine A3 receptor has cardioprotective characteristics which montelukast inhibits, which may make patients susceptible to deleterious cardiac affects. [42]

Gastrointestinal disorders and site of administration ADRs

Montelukast exceeded both beclomethasone and salbutamol’s suspected gastrointestinal (GI) ADR rates per 100,000 R_x at 1.08 versus 0.31 and 0.06, respectively (Table 4). Montelukast caused a greater portion of GI ADRs which may be attributed to montelukast containing a lactose formulation, which certain patients may not respond well to.

There are directions for prescribers to assess whether the patient can tolerate this montelukast formulation by considering hereditary lactose conditions. [15] No fatalities were observed during this study for GI ADRs with non-serious ADRs reported. For abdominal pain, montelukast had a rate of 0.09 per 100,000 R_x whereas beclomethasone and salbutamol had zero. This is consistent to known side effects with montelukast (Table S1), therefore corroborating the validity of the approach using Yellow Card registry data. [8]

Nervous system ADRs

Montelukast had the highest ADR rate at 1.71 per 100,000 R_x, whereas beclomethasone and salbutamol were lower (0.43 and 0.14, respectively). These ADRs share a similar background to psychiatric ADRs with BBB penetrability involved and affecting the dopamine axis. [35-36] Headaches are associated with montelukast at 0.38 per 100,000 Rx whereas for 0.09 and 0.01 for salbutamol and beclomethasone which was validated with comparison to known side effects of montelukast. [8]